JP2011506591A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011506591A5 JP2011506591A5 JP2010538900A JP2010538900A JP2011506591A5 JP 2011506591 A5 JP2011506591 A5 JP 2011506591A5 JP 2010538900 A JP2010538900 A JP 2010538900A JP 2010538900 A JP2010538900 A JP 2010538900A JP 2011506591 A5 JP2011506591 A5 JP 2011506591A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- piperazino
- compound according
- alkyl
- saturated aliphatic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 36
- -1 pyrrolidino, piperidino, piperazino, morpholino Chemical group 0.000 claims 35
- 125000001931 aliphatic group Chemical group 0.000 claims 22
- 125000000217 alkyl group Chemical group 0.000 claims 21
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 12
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 12
- 125000001424 substituent group Chemical group 0.000 claims 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 0 CIN*c1ccnc2nc(*)c(*)nc12 Chemical compound CIN*c1ccnc2nc(*)c(*)nc12 0.000 description 1
- GUMBTPYGNZMDCU-UHFFFAOYSA-N Cc1cc(SC)c(C)cc1 Chemical compound Cc1cc(SC)c(C)cc1 GUMBTPYGNZMDCU-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1501907P | 2007-12-19 | 2007-12-19 | |
| US61/015,019 | 2007-12-19 | ||
| PCT/GB2008/004208 WO2009077766A1 (en) | 2007-12-19 | 2008-12-19 | Pyrido[2,3-b]pyrazine-8-substituted compounds and their use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011506591A JP2011506591A (ja) | 2011-03-03 |
| JP2011506591A5 true JP2011506591A5 (enExample) | 2012-01-12 |
| JP5511680B2 JP5511680B2 (ja) | 2014-06-04 |
Family
ID=40342728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010538900A Active JP5511680B2 (ja) | 2007-12-19 | 2008-12-19 | ピリド［２，３−ｂ］ピラジン−８−置換化合物及びその使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US8198279B2 (enExample) |
| EP (1) | EP2229391B1 (enExample) |
| JP (1) | JP5511680B2 (enExample) |
| KR (1) | KR101665143B1 (enExample) |
| CN (1) | CN101945869B (enExample) |
| AU (1) | AU2008337286B2 (enExample) |
| BR (1) | BRPI0821227A2 (enExample) |
| CA (1) | CA2709257C (enExample) |
| DK (1) | DK2229391T3 (enExample) |
| EA (1) | EA019974B1 (enExample) |
| ES (1) | ES2520940T3 (enExample) |
| IL (1) | IL206330A (enExample) |
| MX (1) | MX2010006739A (enExample) |
| NZ (1) | NZ586418A (enExample) |
| PL (1) | PL2229391T3 (enExample) |
| UA (1) | UA105763C2 (enExample) |
| WO (1) | WO2009077766A1 (enExample) |
| ZA (1) | ZA201004524B (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA105763C2 (uk) | 2007-12-19 | 2014-06-25 | Кансер Рісерч Текнолоджі Лімітед | 8-ЗАМІЩЕНІ ПІРИДО[2,3-b]ПІРАЗИНИ ТА ЇХ ЗАСТОСУВАННЯ |
| GB0807609D0 (en) | 2008-04-25 | 2008-06-04 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| GB0905955D0 (en) | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
| NZ706154A (en) * | 2010-02-01 | 2016-09-30 | Cancer Rec Tech Ltd | 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy |
| US9024041B2 (en) | 2010-04-08 | 2015-05-05 | Respivert Ltd. | P38 MAP kinase inhibitors |
| EP2582700B1 (en) * | 2010-06-17 | 2016-11-02 | Respivert Limited | Respiratory formulations containing p38 mapk inhibitors |
| CA2841142C (en) | 2010-06-23 | 2020-12-15 | Ryan D. Morin | Biomarkers for non-hodgkin lymphomas and uses thereof |
| US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| BR112013005806B1 (pt) | 2010-09-10 | 2022-05-10 | Epizyme, Inc | Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2 |
| MX360254B (es) | 2011-03-10 | 2018-10-26 | Pfizer | Combinacion de terapias inmunomoduladoras local y sistemica para tratamiento mejorado del cancer. |
| EP2508184A1 (en) | 2011-04-06 | 2012-10-10 | Æterna Zentaris GmbH | Pyridopyrazine derivatives and their use |
| TW201733984A (zh) | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| WO2013032951A1 (en) | 2011-08-26 | 2013-03-07 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| EP3332785B1 (en) | 2011-09-14 | 2020-05-06 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| CN103130686B (zh) * | 2011-12-02 | 2016-09-14 | 天津市国际生物医药联合研究院 | N，n′-不对称二芳基取代脲类化合物及其制备方法和用途 |
| EP2806874B1 (en) | 2012-01-25 | 2017-11-15 | Neupharma, Inc. | Quinoxaline-oxy-phenyl derivatives as kinase inhibitors |
| IL296199B2 (en) | 2012-04-13 | 2024-12-01 | Eisai R&D Man Co Ltd | Salt form of a human hi stone methyltransf erase ezh2 inhibitor |
| CN104812389B (zh) | 2012-09-24 | 2020-07-17 | 润新生物公司 | 某些化学实体、组合物及方法 |
| RU2641916C2 (ru) | 2012-10-02 | 2018-01-23 | Байер Кропсайенс Аг | Гетероциклические соединения в качестве пестицидов |
| AU2013331380B2 (en) | 2012-10-15 | 2018-03-22 | Epizyme, Inc. | Substituted benzene compounds |
| WO2014075077A1 (en) | 2012-11-12 | 2014-05-15 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| AU2014337300B2 (en) | 2013-10-16 | 2019-01-03 | Eisai R&D Management Co., Ltd. | Hydrochloride salt form for EZH2 inhibition |
| GB201320729D0 (en) * | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| GB201320732D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Methods of chemical synthesis |
| CN106279147A (zh) * | 2015-05-21 | 2017-01-04 | 中国科学院上海药物研究所 | 一种吡啶并氮杂环化合物及其制备方法和用途 |
| WO2017144877A1 (en) | 2016-02-23 | 2017-08-31 | Cancer Research Technology Limited | Dietary product devoid of at least two non essential amino acids |
| CA3119300A1 (en) | 2017-11-13 | 2019-05-16 | Cancer Research Technology Ltd. | Dietary product |
| GB201809295D0 (en) | 2018-06-06 | 2018-07-25 | Institute Of Cancer Res Royal Cancer Hospital | Lox inhibitors |
| GB201818651D0 (en) | 2018-11-15 | 2019-01-02 | Univ Sheffield | Compounds |
| GB201818649D0 (en) | 2018-11-15 | 2019-01-02 | Univ Sheffield | Compounds |
| GB201818750D0 (en) | 2018-11-16 | 2019-01-02 | Institute Of Cancer Res Royal Cancer Hospital | Lox inhibitors |
| WO2021013712A1 (en) | 2019-07-19 | 2021-01-28 | Anagenesis Biotechnologies S.A.S. | Polyaromatic urea derivatives and their use in the treatment of muscle diseases |
| WO2021023888A1 (en) | 2019-08-08 | 2021-02-11 | B.C.I. Pharma | Isoquinoline derivatives as protein kinase inhibitors |
| US11091447B2 (en) | 2020-01-03 | 2021-08-17 | Berg Llc | UBE2K modulators and methods for their use |
| CN116075238B (zh) | 2020-06-03 | 2025-11-04 | 菲思治疗公司 | 用于个体化治疗方法的制剂 |
| JP2023528930A (ja) | 2020-06-04 | 2023-07-06 | フェス・セラピューティクス，インコーポレーテッド | がんを処置する個別化された方法 |
| WO2021262915A1 (en) * | 2020-06-24 | 2021-12-30 | Purdue Research Foundation | 2,3-disubstituted pyrido[3,4-b]pyrazine-containing compounds as kinase inhibitors |
| CN112480109B (zh) * | 2020-11-16 | 2022-04-01 | 浙江大学 | 吡啶并[2,3-b]吡嗪-3(4H)-酮类衍生物及其用途 |
| EP4029501A1 (en) | 2021-01-19 | 2022-07-20 | Anagenesis Biotechnologies | Combination of polyaromatic urea derivatives and glucocorticoid or hdac inhibitor for the treatment of diseases or conditions associated with muscle cells and/or satellite cells |
| CN114105876A (zh) * | 2021-12-08 | 2022-03-01 | 沈阳科创化学品有限公司 | 一种制备乙唑螨腈中间体的方法 |
| GB202208347D0 (en) | 2022-06-07 | 2022-07-20 | Univ Court Univ Of Glasgow | Targets for cancer therapy |
| GB202209624D0 (en) | 2022-06-30 | 2022-08-17 | Institute Of Cancer Res Royal Cancer Hospital | Prodrugs |
| GB202209622D0 (en) | 2022-06-30 | 2022-08-17 | Institute Of Cancer Res Royal Cancer Hospital | Compounds |
| EP4622971A1 (en) | 2022-11-24 | 2025-10-01 | B.C.I. Pharma | Pyridine derivatives as protein kinase inhibitors |
| CN115884487B (zh) * | 2023-02-16 | 2023-05-26 | 浙大城市学院 | 基于针式协同双螺旋电极介质阻挡放电管 |
| WO2024235115A1 (zh) * | 2023-05-12 | 2024-11-21 | 正大天晴药业集团股份有限公司 | 含有芳香双并环的化合物 |
| WO2025021943A1 (en) | 2023-07-26 | 2025-01-30 | Neuralis | Quinazolinone, benzoxazinone and benzoxazepinone derivatives as protein kinase inhibitors |
| WO2025229029A1 (en) | 2024-04-30 | 2025-11-06 | Gorgoulis Vassilis G | Conjugate of a senotherapeutic moiety and a lipid-targeting moiety |
Family Cites Families (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4082845A (en) | 1977-04-25 | 1978-04-04 | Merck & Co., Inc. | 3-(1-Piperazinyl)-pyrido[2,3-b]pyrazines |
| JPS5665863A (en) | 1979-10-31 | 1981-06-03 | Tokyo Organ Chem Ind Ltd | Novel aniline derivative, its preparation and pesticide containing the same |
| JPS5738777A (en) | 1980-08-19 | 1982-03-03 | Sogo Yatsukou Kk | 2-sufanilamidopyrathyn derivative |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5643755A (en) | 1994-10-07 | 1997-07-01 | Regeneron Pharmaceuticals Inc. | Nucleic acid encoding tie-2 ligand |
| US5879672A (en) | 1994-10-07 | 1999-03-09 | Regeneron Pharmaceuticals, Inc. | Tie-2 ligand 1 |
| AU701568B2 (en) | 1994-09-22 | 1999-02-04 | Licentia Ltd | Promoter for the receptor tyrosine kinase, tie |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| WO1997017329A1 (en) * | 1995-11-07 | 1997-05-15 | Kirin Beer Kabushiki Kaisha | Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same |
| ZA971896B (en) | 1996-03-26 | 1998-09-07 | Du Pont Merck Pharma | Aryloxy-and arythio-fused pyridines and pyrimidines and derivatives |
| CA2744096C (en) | 1996-07-31 | 2013-07-30 | Laboratory Corporation Of America Holdings | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| WO1998013350A1 (en) | 1996-09-25 | 1998-04-02 | Zeneca Limited | Qinoline derivatives inhibiting the effect of growth factors such as vegf |
| US6030831A (en) | 1997-09-19 | 2000-02-29 | Genetech, Inc. | Tie ligand homologues |
| US6093728A (en) | 1997-09-26 | 2000-07-25 | Asta Medica Aktiengesellschaft | Methods of modulating serine/threonine protein kinase function with azabenzimidazole-based compounds |
| GB9721437D0 (en) | 1997-10-10 | 1997-12-10 | Glaxo Group Ltd | Heteroaromatic compounds and their use in medicine |
| EP1449834A3 (en) * | 1997-12-22 | 2004-12-22 | Bayer Corporation | Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas |
| US20010053946A1 (en) * | 1998-09-04 | 2001-12-20 | R. R. Donnelley & Sons Company | System for controlling feeders of a package assembly apparatus |
| EP1143957A3 (en) | 1998-12-16 | 2002-02-27 | Warner-Lambert Company | Treatment of arthritis with mek inhibitors |
| EP1140062B1 (en) | 1999-01-07 | 2005-04-06 | Warner-Lambert Company LLC | Treatment of asthma with mek inhibitors |
| JP3519368B2 (ja) * | 1999-01-22 | 2004-04-12 | 麒麟麦酒株式会社 | キノリン誘導体およびキナゾリン誘導体 |
| AU3475900A (en) | 1999-01-29 | 2000-08-18 | University Of Akron, The | Polyimides used as microelectronic coatings |
| CN1373660A (zh) | 1999-07-16 | 2002-10-09 | 沃尼尔·朗伯公司 | 使用mek抑制剂治疗慢性疼痛的方法 |
| CN1391562A (zh) * | 1999-09-21 | 2003-01-15 | 阿斯特拉曾尼卡有限公司 | 用作药物的喹唑啉衍生物 |
| GB2356398A (en) | 1999-11-18 | 2001-05-23 | Lilly Dev Ct S A | Preparation of arylsulfamides |
| AU2728201A (en) | 1999-12-21 | 2001-07-03 | Sugen, Inc. | 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors |
| US6492529B1 (en) | 2000-01-18 | 2002-12-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Bis pyrazole-1H-pyrazole intermediates and their synthesis |
| EP1341771A2 (en) | 2000-11-29 | 2003-09-10 | Glaxo Group Limited | Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors |
| KR20020096367A (ko) | 2001-06-19 | 2002-12-31 | 주식회사 티지 바이오텍 | 관절염 예방 또는 치료제 및 그것의 스크리닝 방법 |
| BRPI0214840B8 (pt) | 2001-12-21 | 2021-05-25 | The Wellcome Trust | métodos para a detecção de mutações oncogênicas humanas, métodos automatizados para detectar uma mutação e método e ensaio para identificar um ou mais compostos tendo atividade anti-proliferativa |
| US20030180226A1 (en) | 2002-01-23 | 2003-09-25 | Haughton Pauline A. | Anti-bacterial sneeze spray |
| AU2003257170B2 (en) | 2002-08-09 | 2008-12-11 | Merck Sharp & Dohme Corp. | Tyrosine kinase inhibitors |
| EP1604037A1 (en) | 2003-03-20 | 2005-12-14 | Universite Catholique De Louvain | Medical use of ras antagonists for the treatment of capillary malformation |
| AU2004246800B2 (en) | 2003-06-13 | 2008-12-04 | Novartis Ag | 2-aminopyrimidine derivatives as Raf kinase inhibitors |
| AU2005215257A1 (en) | 2004-02-13 | 2005-09-01 | Pfizer Products Inc. | Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists |
| TW200538120A (en) | 2004-02-20 | 2005-12-01 | Kirin Brewery | Compound having TGF-beta inhibitory activity and pharmaceutical composition containing same |
| TW200616974A (en) | 2004-07-01 | 2006-06-01 | Astrazeneca Ab | Chemical compounds |
| EP1789399A1 (en) | 2004-08-31 | 2007-05-30 | AstraZeneca AB | Quinazolinone derivatives and their use as b-raf inhibitors |
| MX2007004480A (es) | 2004-10-15 | 2007-05-08 | Astrazeneca Ab | Quinoxalinas como inhibidores b raf. |
| GB0423554D0 (en) | 2004-10-22 | 2004-11-24 | Cancer Rec Tech Ltd | Therapeutic compounds |
| GB0428082D0 (en) * | 2004-12-22 | 2005-01-26 | Welcome Trust The Ltd | Therapeutic compounds |
| JP5197016B2 (ja) | 2004-12-23 | 2013-05-15 | デシファラ ファーマスーティカルズ， エルエルシー | 酵素モジュレータ及び治療 |
| WO2007059202A2 (en) | 2005-11-15 | 2007-05-24 | Bayer Healthcare Ag | Pyrazolyl urea derivatives useful in the treatment of cancer |
| JP2009518298A (ja) | 2005-12-01 | 2009-05-07 | バイエル ヘルスケア リミティド ライアビリティ カンパニー | 癌治療に有用な尿素化合物 |
| ZA200804679B (en) | 2005-12-08 | 2010-02-24 | Millenium Pharmaceuticals Inc | Bicyclic compounds with kinase inhibitory activity |
| US7989461B2 (en) | 2005-12-23 | 2011-08-02 | Amgen Inc. | Substituted quinazolinamine compounds for the treatment of cancer |
| CN101040720A (zh) | 2006-03-24 | 2007-09-26 | 沈华立 | 一种豆腐干的五香麻辣卤汤液 |
| US20090149484A1 (en) * | 2006-04-18 | 2009-06-11 | Astrazeneca Ab | Quinazolin-4-one derivatives, process for their preparation and pharmaceutical compositions containing them |
| US7951819B2 (en) | 2006-04-26 | 2011-05-31 | Cancer Research Technology Limited | Imidazo[4, 5-B]pyridin-2-one and oxazolo[4, 5-B] pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds |
| EP1992628A1 (en) | 2007-05-18 | 2008-11-19 | Glaxo Group Limited | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones |
| US8227603B2 (en) | 2006-08-01 | 2012-07-24 | Cytokinetics, Inc. | Modulating skeletal muscle |
| WO2008044688A1 (en) | 2006-10-11 | 2008-04-17 | Daiichi Sankyo Company, Limited | Urea derivative |
| EP2446903B1 (en) | 2006-11-20 | 2019-10-09 | President and Fellows of Harvard College | Compositions for treating itch |
| CA2692861A1 (en) | 2007-07-10 | 2009-01-15 | Neurim Pharmaceuticals (1991) Ltd. | Cd44 splice variants in neurodegenerative diseases |
| UA105763C2 (uk) | 2007-12-19 | 2014-06-25 | Кансер Рісерч Текнолоджі Лімітед | 8-ЗАМІЩЕНІ ПІРИДО[2,3-b]ПІРАЗИНИ ТА ЇХ ЗАСТОСУВАННЯ |
| GB0807609D0 (en) | 2008-04-25 | 2008-06-04 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| EP2288922B1 (en) | 2008-05-08 | 2016-08-17 | University of Utah Research Foundation | Sensory receptors for chronic fatigue and pain and uses thereof |
| GB0818033D0 (en) | 2008-10-02 | 2008-11-05 | Respivert Ltd | Novel compound |
| BRPI0920707A2 (pt) | 2008-10-02 | 2015-12-29 | Respivert Ltd | compostos |
| WO2010067130A1 (en) | 2008-12-11 | 2010-06-17 | Respivert Limited | P38 map kinase inhibitors |
| GB0905955D0 (en) | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
| WO2011004276A1 (en) | 2009-07-06 | 2011-01-13 | Pfizer Limited | Hepatitis c virus inhibitors |
| JP2013502236A (ja) | 2009-08-24 | 2013-01-24 | ジェネンテック， インコーポレイテッド | Ｋｒａｓ変異及びｒｔｋ発現レベルを検出することによるｂ−ｒａｆ阻害剤治療に対する細胞の感受性の決定 |
| GB0918249D0 (en) | 2009-10-19 | 2009-12-02 | Respivert Ltd | Compounds |
| GB0921731D0 (en) | 2009-12-11 | 2010-01-27 | Respivert Ltd | Theraputic uses |
| GB0921730D0 (en) | 2009-12-11 | 2010-01-27 | Respivert Ltd | Method of treatment |
| NZ706154A (en) | 2010-02-01 | 2016-09-30 | Cancer Rec Tech Ltd | 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy |
| GB201005589D0 (en) | 2010-04-01 | 2010-05-19 | Respivert Ltd | Novel compounds |
| JP5787976B2 (ja) | 2010-04-08 | 2015-09-30 | レスピバート・リミテツド | Ｐ３８ｍａｐキナーゼ阻害剤としてのピラゾリルウレア |
| US9024041B2 (en) | 2010-04-08 | 2015-05-05 | Respivert Ltd. | P38 MAP kinase inhibitors |
| EP2582700B1 (en) | 2010-06-17 | 2016-11-02 | Respivert Limited | Respiratory formulations containing p38 mapk inhibitors |
| GB201010196D0 (en) | 2010-06-17 | 2010-07-21 | Respivert Ltd | Methods |
| GB201010193D0 (en) | 2010-06-17 | 2010-07-21 | Respivert Ltd | Medicinal use |
| WO2012008564A1 (ja) | 2010-07-16 | 2012-01-19 | 協和発酵キリン株式会社 | 含窒素芳香族複素環誘導体 |
| UY33337A (es) | 2010-10-18 | 2011-10-31 | Respivert Ltd | DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS |
| WO2012149547A1 (en) | 2011-04-28 | 2012-11-01 | Duke University | Methods of treating hemoglobinopathies |
| JP6223329B2 (ja) | 2011-06-23 | 2017-11-01 | ヴィアメット ファーマスーティカルズ，インコーポレイテッド | 金属酵素化合物 |
| WO2013001372A2 (en) | 2011-06-30 | 2013-01-03 | University Of Oslo | Methods and compositions for inhibition of activation of regulatory t cells |
| MX2014002480A (es) | 2011-09-01 | 2014-03-27 | Novartis Ag | Uso del compuesto organico para el tratamiento del sindrome de noonan. |
| JP2014528404A (ja) | 2011-10-03 | 2014-10-27 | レスピバート・リミテツド | ｐ３８ＭＡＰキナーゼ阻害剤としての１−ピラゾリル−３−（４−（（２−アニリノピリミジン−４−イル）オキシ）ナフタレン−１−イル）尿素 |
| EP2578582A1 (en) | 2011-10-03 | 2013-04-10 | Respivert Limited | 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors |
| GB201214750D0 (en) | 2012-08-17 | 2012-10-03 | Respivert Ltd | Compounds |
| US9783556B2 (en) | 2012-08-29 | 2017-10-10 | Respivert Limited | Kinase inhibitors |
| EP2890695A2 (en) | 2012-08-29 | 2015-07-08 | Respivert Limited | Kinase inhibitors |
| EP2890460B1 (en) | 2012-08-29 | 2017-02-22 | Respivert Limited | Kinase inhibitors |
| GB201215357D0 (en) | 2012-08-29 | 2012-10-10 | Respivert Ltd | Compounds |
| EP2925742B1 (en) | 2012-11-16 | 2016-10-26 | Respivert Limited | Kinase inhibitors |
| WO2014140582A1 (en) | 2013-03-14 | 2014-09-18 | Respivert Limited | Kinase inhibitors |
| JO3279B1 (ar) | 2013-03-15 | 2018-09-16 | Respivert Ltd | مشتقات 2-((4- امينو -3- (3- فلورو-5- هيدروكسي فينيل)-h1- بيرازولو [d-3,4] بيرمدين-1-يل )ميثيل )- 3- (2- تراي فلورو ميثيل ) بينزيل ) كوينازولين -4 (h3)- واحد واستخدامها كمثبطات فوسفواينوسيتايد 3- كاينيز |
| MX363949B (es) | 2013-04-02 | 2019-04-08 | Topivert Pharma Ltd | Inhibidor de quinasa. |
| US9771353B2 (en) | 2013-04-02 | 2017-09-26 | Topivert Pharma Limited | Kinase inhibitors based upon N-alkyl pyrazoles |
| GB201320729D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| WO2015092423A1 (en) | 2013-12-20 | 2015-06-25 | Respivert Limited | Urea derivatives useful as kinase inhibitors |
| EP3105222B1 (en) | 2014-02-14 | 2018-04-11 | Respivert Limited | Aromatic heterocyclic compounds as antiinflammatory compounds |
| MA40774A (fr) | 2014-10-01 | 2017-08-08 | Respivert Ltd | Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38 |
| EP3201189A1 (en) | 2014-10-01 | 2017-08-09 | Respivert Limited | N-phenyl-3-quinazolin-6-yl-benzamide derivatives as p38 kinase inhibitors |
-
2008
- 2008-12-19 UA UAA201008265A patent/UA105763C2/uk unknown
- 2008-12-19 WO PCT/GB2008/004208 patent/WO2009077766A1/en not_active Ceased
- 2008-12-19 AU AU2008337286A patent/AU2008337286B2/en not_active Ceased
- 2008-12-19 JP JP2010538900A patent/JP5511680B2/ja active Active
- 2008-12-19 EP EP08862089.3A patent/EP2229391B1/en active Active
- 2008-12-19 NZ NZ586418A patent/NZ586418A/xx unknown
- 2008-12-19 PL PL08862089T patent/PL2229391T3/pl unknown
- 2008-12-19 CN CN200880126717.3A patent/CN101945869B/zh not_active Expired - Fee Related
- 2008-12-19 BR BRPI0821227-9A patent/BRPI0821227A2/pt not_active Application Discontinuation
- 2008-12-19 DK DK08862089.3T patent/DK2229391T3/da active
- 2008-12-19 US US12/808,249 patent/US8198279B2/en not_active Expired - Fee Related
- 2008-12-19 MX MX2010006739A patent/MX2010006739A/es active IP Right Grant
- 2008-12-19 ES ES08862089.3T patent/ES2520940T3/es active Active
- 2008-12-19 CA CA2709257A patent/CA2709257C/en not_active Expired - Fee Related
- 2008-12-19 KR KR1020107015083A patent/KR101665143B1/ko not_active Expired - Fee Related
- 2008-12-19 EA EA201070667A patent/EA019974B1/ru not_active IP Right Cessation
-
2010
- 2010-06-13 IL IL206330A patent/IL206330A/en active IP Right Grant
- 2010-06-25 ZA ZA2010/04524A patent/ZA201004524B/en unknown
-
2012
- 2012-04-28 US US13/459,120 patent/US8546387B2/en not_active Expired - Fee Related
-
2013
- 2013-09-24 US US14/035,133 patent/US8912191B2/en not_active Expired - Fee Related
-
2014
- 2014-11-17 US US14/543,379 patent/US9155737B2/en not_active Expired - Fee Related
-
2015
- 2015-09-14 US US14/853,199 patent/US9540372B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011506591A5 (enExample) | ||
| JP2020506178A5 (enExample) | ||
| JP2009534457A5 (enExample) | ||
| JP2004511462A5 (enExample) | ||
| JP2019501223A5 (enExample) | ||
| JP2001510843A5 (enExample) | ||
| JP2019500315A5 (enExample) | ||
| JP2009536620A5 (enExample) | ||
| JP2014520898A5 (enExample) | ||
| WO2010042684A4 (en) | Pyrrolotriazine kinase inhibitors | |
| JP2010536887A5 (enExample) | ||
| JP2002543185A5 (enExample) | ||
| JP2017538677A5 (enExample) | ||
| JP2005519908A5 (enExample) | ||
| JP2017501236A5 (enExample) | ||
| JP2010524932A5 (enExample) | ||
| JP2003520195A5 (enExample) | ||
| ES533069A0 (es) | Procedimiento para preparar derivados de piperazina | |
| CA2406392A1 (en) | Substituted benzoic acid amides and use thereof for the inhibition of angiogenesis | |
| JP2006519852A5 (enExample) | ||
| JP2011505356A5 (enExample) | ||
| JPH10287651A5 (enExample) | ||
| JP2018525430A5 (enExample) | ||
| JPH05509307A (ja) | プリンの抗ウイルス性ホスホノ―アルケン誘導体 | |
| JP2003528084A5 (enExample) |